Name: Savill_March2026_CMDB_edited_x110
Uploaded: 2026-03-17T16:59:34.858Z
Duration: 2 min 55 s

Browse every publication tagged Breast cancer

October 2026
Quality of care in US community oncology practices among patients with metastatic breast cancer and metastatic non-small cell lung cancer
May 2026
Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)
May 2026
Real-world post-progression outcomes following 1L ribociclib + aromatase inhibitor (AI) versus Al alone in African American and low socio-economic status patients with HR+/HER2- mBC in US
May 2026
Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease
- Breast cancer
- Artificial intelligence
February 2026
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer
- Breast cancer
January 2026
Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data
- Breast cancer
December 2025
Personalized acquired CDK4/6i resistance: Associations with baseline characteristics like obesity in real-world clinical-multiomics data
- Breast cancer
December 2025
Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer
- Breast cancer
December 2025
Real-world overall survival with palbociclib plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer who are overweight/obese
- Breast cancer